Best Dihexa Telehealth Providers for Cognitive health and brain function

Dihexa is described in its original research (Joseph et al., WSU) as being 10 million times more potent than BDNF in promoting synaptogenesis in animal models. In terms of practical cognitive enhancement, users report it as among the most noticeable single-compound nootropics — more so than racetams, modafinil, or most peptide nootropics.

Yes — unlike most peptides, Dihexa is a peptidomimetic (a non-peptide compound that mimics a peptide's activity) with favorable oral bioavailability and ability to cross the blood-brain barrier. It is also used transdermally. Oral dosing is typically 5–35mg per week (not daily — due to long duration of action and potency).

Dihexa was originally developed at Washington State University with Alzheimer's disease in mind — HGF/Met signaling loss is a feature of AD pathology. It has shown memory restoration in aged and Alzheimer's mouse models. No human clinical trials are published as of 2025, but it is of significant research interest.

Promoting synaptogenesis theoretically could enhance existing connections non-selectively, including those encoding fear, trauma, or maladaptive patterns. There are also theoretical concerns about excessive synaptic growth in oncological contexts. These theoretical risks have not materialized in animal studies, but long-term human safety data is absent. Caution and physician supervision are warranted.